Literature DB >> 2676224

Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

S S Bielack1, R Erttmann, G Looft, C Purfürst, G Delling, K Winkler, G Landbeck.   

Abstract

Preoperative chemotherapy according to the COSS 86 protocol, including two courses of cisplatin, was used for high-risk osteosarcoma. Patients were randomised to receive either intraarterial (i.a.) or intravenous (i.v.) cisplatin infusions. As measured by flameless atomic absorption spectroscopy (FAAS), platinum (Pt) levels in serum, ultrafiltrate, and urine did not show a decrease in systemic drug availability with i.a. administration. Tumors were surgically removed 3 weeks after the last cisplatin dose and analysed for Pt content and response to chemotherapy. A correlation could not be demonstrated between Pt levels in tumor tissue samples and the mode of CDDP application or extent of tumor cell destruction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676224     DOI: 10.1007/bf00257446

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  [Simplified metacrylate embedding method for undecalcified bone sections].

Authors:  G Delling
Journal:  Beitr Pathol       Date:  1972

2.  Clinical kinetics on intact cisplatin and some related species.

Authors:  K J Himmelstein; T F Patton; R J Belt; S Taylor; A J Repta; L A Sternson
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

3.  Pharmacologic rationale for regional drug delivery.

Authors:  J M Collins
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

4.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

5.  cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.

Authors:  J J Ochs; A I Freeman; H O Douglass; D S Higby; E R Mindell; L F Sinks
Journal:  Cancer Treat Rep       Date:  1978-02

6.  Regional chemotherapy with the use of cisplatin and doxorubicin as primary treatment for advanced sarcomas in shoulder, pelvis, and thigh.

Authors:  F O Stephens; M H Tattersall; W Marsden; R C Waugh; D Green; S W McCarthy
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

7.  Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity.

Authors:  L J Ettinger; H O Douglass; E R Mindell; L F Sinks; C K Tebbi; D Risseeuw; A I Freeman
Journal:  J Clin Oncol       Date:  1986-03       Impact factor: 44.544

8.  Drug streaming during intra-arterial chemotherapy.

Authors:  J B Blacklock; D C Wright; R L Dedrick; R G Blasberg; R J Lutz; J L Doppman; E H Oldfield
Journal:  J Neurosurg       Date:  1986-02       Impact factor: 5.115

9.  Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.

Authors:  K Winkler; G Beron; R Kotz; M Salzer-Kuntschik; J Beck; W Beck; W Brandeis; W Ebell; R Erttmann; U Göbel; W Havers; G Henze; L Hinderfield; P Höcker; A Jobke; H Jürgens; H Kabisch; G Landbeck; P Preusser; G Prindull; W Ramach; J Ritter; J Sekera; J Treuner; G Wüst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

10.  Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer.

Authors:  B Hecquet; P Vennin; C Fournier; B Poissonnier
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

View more
  5 in total

1.  Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.

Authors:  J Hannemann; K Baumann
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  Pharmacokinetics and results of dose escalation in cis-platin hyperthermic isolation limb perfusion.

Authors:  W S Fletcher; R F Pommier; E A Woltering; C R Mueller; K O Ash; K A Small
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

3.  Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

Authors:  H J Guchelaar; H J Hoekstra; E G de Vries; D R Uges; J W Oosterhuis; H Schraffordt Koops
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

4.  The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.

Authors:  Sophie Rae; Cathy Spillane; Gordon Blackshields; Stephen F Madden; Joanne Keenan; Britta Stordal
Journal:  Hum Cell       Date:  2022-07-06       Impact factor: 4.374

5.  Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation.

Authors:  Khaldoun Al-Romaih; Gino R Somers; Jane Bayani; Simon Hughes; Mona Prasad; Jean-Claude Cutz; Hui Xue; Maria Zielenska; Yuzhuo Wang; Jeremy A Squire
Journal:  Cancer Cell Int       Date:  2007-09-10       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.